
Sanofi to Acquire Vigil Neuroscience, Boosting Alzheimer’s Drug Pipeline
Sanofi to Acquire Vigil Neuroscience in $470 Million Deal, Bolstering Neurology Pipeline with Promising Alzheimer’s Drug Candidate In a strategic move that further solidifies its commitment to neurological disorders, Sanofi announced it has entered into a definitive agreement to acquire…











